Johnson & Johnson agreed to acquire Ollin Biosciences for US$2.2 billion upfront. The agreement includes up to US$1.1 billion in additional regulatory and commercial milestone payments. Ollin is a clinical-stage biopharmaceutical company focused on therapies for serious eye diseases.
Deal terms
The deal is expected to close by the end of 2026. It remains subject to regulatory approvals and other customary closing conditions. Goldman Sachs served as lead financial advisor to Ollin, with Centerview Partners also advising.
Company origins
Ollin was founded in 2023 to identify and advance next-generation ophthalmology therapies. ARCH Venture Partners, Monograph Capital, and Mubadala incubated the company. Earlier this year, TCGX and a syndicate of healthcare-focused investors supported late-stage development of OLN324.
Lead program
Ollin’s lead program is OLN324, a Phase 3 investigational bispecific antibody. It targets VEGF and Ang2 with optimized molecular size and potency. The therapy is being developed for wet age-related macular degeneration and diabetic macular edema.
Subject to completion, Ollin plans to build on its progress and advance OLN324 with Johnson & Johnson. The two diseases affect more than 40 million people worldwide. Retina therapeutics is a US$15 billion worldwide market.